# Wim De Vlieger

**Partner** 

wdevlieger@gibsondunn.com

T: +44 20 7071 4279

London

Wim De Vlieger is a partner in the London office of Gibson Dunn. Wim is Co-Chair of Private Equity in Europe and a member of the Mergers and Acquisitions and Capital Markets Practice Groups.

Wim advises private equity investors and their portfolio companies on a wide range of corporate transactions, including growth equity and control investments and coinvestments, structured transactions, buy-out transactions, mergers and acquisitions, and exits. He also has considerable experience advising on strategic cross-border M&A transactions and on international capital market transactions. He has broad experience counselling clients across a wide range of European jurisdictions, with a focus on transactions in the technology and life sciences sectors.

Wim is recognised by *The Legal 500 UK* 2024 for Private Equity: Transactions – High-Value Deals, M&A: Upper Mid-Market and Premium Deals £750 million+. He is also recognised by the 2025 edition of *Best Lawyers in the United Kingdom* as a leading lawyer for Private Equity Law.

Wim received an LL.M. from the University of Pennsylvania Law School in 2007, a M.S. from HEC Paris in 2003 and a Masters of Law (cum laude) from the University of Leuven in 2002. He is admitted to practice in New York. He speaks Dutch and French.

### Selected experience:\*

- Arvelle Therapeutics, a Swiss-based biopharmaceutical company, on its sale to Angelini Pharma for a total cash consideration of up to \$960 million.
- Gilde Buy Out Partners in its investment in Caseking, a supplier of highperformance PC gaming equipment and peripherals.
- Goldman Sachs Private Capital, including on its:
  - investment and follow-on investment in Wolt, a delivery platform active in 18 countries;
  - investment in DocPlanner Group, an international healthcare booking platform provider; and
  - o investment in technology platform LumApps.
- Kiniciti, a Welsh Carson, Anderson & Stowe platform, in its control investment in Ncardia, a company focused on developing stem cell-based solutions for drug discovery and cell therapy.
- KKR, including on its:
  - control investment in Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company headquartered in



## **Capabilities**

Private Equity
Capital Markets
Life Sciences
Mergers and Acquisitions

#### **Credentials**

#### **Education**

University of Pennsylvania - 2007 Master of Laws (LL.M.)

Hautes études commerciales de Paris-HEC Paris - 2003 Master of Science Catholic University of Leuven - 2002 Master of Laws (LL.M.)

#### Admissions

New York Bar

England & Wales - Solicitor - Registered Foreign Lawyer

Belgium - Flemish Bar - Registered Foreign Lawyer

#### Switzerland;

- o investment in Leapwork, a Danish no-code automation platform;
- investment and follow-on investment in Feedzai, a leading cloud-based financial risk management platform based in Portugal;
- acquisition of Argenta, a leading animal pharmaceutical research and manufacturing company;
- o control investment in ReliaQuest, a cybersecurity technology company;
- investment in Zwift, the at home training game connecting cyclists around the world;
- investment and follow-on investment in music platform Artlist in Israel, and on Artlist's acquisition of Motion Array in the U.S.;
- o exit from Paris-based company Ivalua; and
- initial investment in, follow-on investment in and exit from KnowBe4, a security awareness training and simulated phishing platform provider.
- KKR and Goldman Sachs Private Capital on their respective investments in OutSystems, the global leader in low-code rapid application development, as part of a \$360 million investment round.
- NXP Semiconductors, on its merger with Freescale, on various issuances of senior cross-over notes and secured and unsecured high-yield notes, and on its initial public offering on NASDAQ and subsequent secondary offerings.

\*Some of these representations occurred prior to Wim's association with Gibson Dunn.

# Wim De Vlieger Partner

wdevlieger@gibsondunn.com

T: +44 20 7071 4279

London